Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Novartis division launches biosimilar somatropin

Novartis division launches biosimilar somatropin

5th October 2009

Novartis division Sandoz has announced the launch of its human growth hormone somatropin, following the drug’s approval in June 2009 for the treatment of growth hormone deficiency in children and growth disturbance associated with Turner’s syndrome or chronic renal insufficiency.

The release of the drug may lead the way for greater access to such treatments in the Asian market, the firm added, as it is the first-ever biosimilar to be launched in Japan – the world’s second-largest pharmaceuticals market.

Recombinant human growth hormone somatropin is currently marketed as Omnitrope in the EU, the US and Australia.

Chief executive of Sandoz Jeff George said: “Biopharmaceuticals offer real therapeutic hope to those suffering from the most complex diseases of modern society.”

At the end of last month, Novartis revealed the positive results of a phase III trial into its oral multiple sclerosis treatment FT720.

The study found that the drug displayed the capability to reduce the relapse rate of patients suffering from the condition by 54 to 60 per cent when compared to a placebo.

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.